Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. Co. is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). In addition, Co. is evaluating a peptide that may be used to slow the transmission of SARS-CoV-2 (HT-002). Co. is also developing a diagnostic device via a mobile device. Co. has interests in assets being developed by third parties including a treatment for patients with lupus. The HOTH stock yearly return is shown above.
The yearly return on the HOTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HOTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|